On the evening of March 28, Hisun Pharmaceuticals (600267) announced its 2024 annual report. The report shows that the company achieved operating income of 9.787 billion yuan and a net profit of 601 million yuan in 2024. The company said that the performance was able to turn losses into profits, mainly due to the promotion of preparation products, the growth of pharmaceutical raw material business, the increase in sales profit, and the company's improvement of management efficiency, optimization of resource allocation and utilization efficiency.

At the same time, Hisun Pharmaceuticals actively returns to shareholders, and plans to pay cash dividends of 2.10 yuan (including tax) for every 10 shares in 2024. In addition, in 2024, the company adopted a centralized bidding method to implement a share repurchase amount of 96.4589 million yuan, and the cash dividend and repurchase amount totaled 342 million yuan, accounting for 56.87% of the net profit attributable to the parent company.

In its annual report, Hisun Pharmaceuticals stated that through a series of changes and transformations, the company has promoted the sustainable and healthy development of various business sectors. The comprehensive strength of the pharmaceutical preparation business has increased, and the company's ranking in the IQVIA Chinese Pharmaceutical Company Authoritative List has jumped 12 places to 26th, and has consolidated its benchmark position in the three key track areas of lipid-lowering, anti-infection and hormones, demonstrating its leading advantages. The sales volume of the key product Sesme in 2024 will be 6.2569 million boxes, an increase of 31% year-on-year, and it will continue to improve its position in the field of cholesterol treatment.

In terms of API business, Hisun Pharmaceuticals actively consolidates and expands domestic and foreign markets, the human medicine business has grown steadily, the CMO business sales have increased significantly, and the revenue of products such as Infumafungin and Orlistat has increased significantly year-on-year. As one of the emerging businesses that Hisun Pharmaceutical focuses on cultivating, the animal medicine business will continue to expand in 2024. Four new drugs, including Yunyuanqing, the first blockbuster product in the field of animal health vaccines of Hisun, and Haimiaoduo, the first pet vaccine, will be launched. The sales of key veterinary products will continue to rise, with a total of 9 single products selling over 10 million, among which the annual sales of Hailemiao, the star product of pet deworming, have exceeded 100 million for many consecutive years.

In terms of R&D, Hisun Pharmaceutical has always attached great importance to innovative R&D and external cooperation and exchanges. It is understood that in 2024, the company will achieve scientific research efficiency improvement through strategic R&D resource reconstruction, focus on strengthening resource allocation in core treatment areas such as cardiovascular and metabolic, and build a cross-departmental collaborative R&D framework. In order to accelerate the process of innovative drugs, the company has established a new Shanghai Innovative Drug R&D Center and reached strategic cooperation with top domestic and foreign scientific research institutions and enterprises such as Derui Pharmaceuticals, Nobel Prize Team, and Institute of Microbiology of the Chinese Academy of Sciences. At the same time, the company has promoted the establishment of advanced R&D platforms such as small nucleic acids, complex preparations, and AI, and incubated a number of potential new projects, among which the HS387 project has completed Pre-IND application; a total of 10 drug registration approvals have been obtained, 12 domestic and foreign registration applications have been submitted, 42 new R&D projects have been launched, 62 patent applications have been filed, and 30 patents have been authorized throughout the year.

https://finance.eastmoney.com/a/202503303360273069.html